Secondary hormonal manipulation of prostate cancer

Seminars in Urologic Oncology

Volumn 20, Issue 3 SUPPL. 1, 2002, Pages 24-30

  Small, Eric J ^a   Harris, Katherine A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CORTICOSTEROID; DEXAMETHASONE; FLUTAMIDE; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; MEGESTROL ACETATE; MITOXANTRONE; NILUTAMIDE; PC SPES;

ADVANCED CANCER; ANDROGEN SYNTHESIS; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG WITHDRAWAL; HORMONE RESISTANCE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0036671915     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.35054     Document Type: Article

References (52)

1. Cancer Statistics 2002
2. Carcinoma of the prostate
3. The present position of the surgery of the hypertrophied prostate
4. Studies on prostatic cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
5. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
6. Combined androgen blockade for the treatment of metastatic carcinoma of the prostate
7. Hormone-refractory prostate cancer: Refining the concept
8. Prostate specific antigen decline after antiandrogen withdrawal
9. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal
10. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
11. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer
12. Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome
13. Antiandrogen withdrawal syndrome with nilutamide
14. Antiandrogen withdrawal syndrome with nilutamide
15. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome
16. Antiandrogen withdrawal syndrome in prostate cance after treatment with steroidal antiandrogen chlormadinone acetate
17. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol
18. A double-blind assessment of antiandrogen withdrawal from casodex (C) or eulexin (E) therapy while continuing luteinizing hormone releasing hormone analogue (LHRH-a) therapy for patients with stage d2 prostate cancer
19. Aberrant response in vitro of hormone-responseive prostate cancer cells to antiandrogens
20. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate
21. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
22. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
23. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment
24. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group
25. Bicalutamide for advanced prostate cancer: The natural history versus treated history of disease
26. Studies on the human prostatic cancer cell line LNCaP
27. High-dose bicalutamide for androgen-independent prostate cancer: Effect of prior hormonal therapy
28. Nilutamide response after flutamide failure in postorchiectomy progressive prostate cancer
29. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
30. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of 'hormone-refractory' prostate cancer
31. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
32. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma
33. Treatment of metastatic prostate cancer with low-dose prednisone: Evalutaion of pain and quality of life as pragmatic indices of response
34. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
35. Antitumor activity of suramin in hormone-refractory prostate cancer when hydrocortisone treatment and flutamide withdrawal are prospectively controlled for as potentially confounding variables
36. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
37. Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer
38. Hydrocortisone with and without mitoxantrone in patients with hormone-refractory prostate cancer: Preliminary results from a prospective randomized Cancer and Leukemia Group B trial (9182) comparing chemotherapy to best supportive care
39. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
40. Megestrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): Prostate specific antigen (PSA) response and antiandrogen withdrawal (AAWD): Cancer and Leukemia Group B (CALGB) 9181
41. Megestrol acetate in the treatment of hormone refractory prostate cancer
42. Effects of baicalein and esculetin on transduction signals and growth factor expression in T-lymphoid leukemia cells
43. Effect of glycyrrhetinic acid on DNA damage and unscheduled DNA synthesis induced by benzo(alpha) pyrene
44. Inhibition of tumor angiogenesis and metastasis by saponin of Panax ginseng, ginsenoside-Rb 2
45. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES
46. PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo
47. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer
48. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
49. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease
50. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
51. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
52. Hormonally relapsed prostatic cancer: Lessons from the flutamide withdrawal syndrome